Tenax Therapeutics Income Statement (2010-2026) | TENX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jul2010 Oct2010 Jan2011 Apr2011 Jul2011 Oct2011 Jan2012 Apr2012 Jul2012 Oct2012 Jan2013 Apr2013 Jul2013 Oct2013 Jan2014 Apr2014 Jul2014 Oct2014 Jan2015 Apr2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
Revenue & cost
Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Research & Development (Quarter)
0.69M1.16M0.92M1.18M1.52M1.54M1.13M0.27M0.20M1.07M1.70M2.68M2.33M3.11M4.59M5.68M6.12M10.33M10.54M11.54M
Selling, General & Administrative (Quarter)
1.27M2.64M2.30M1.54M1.34M1.38M1.42M1.27M1.04M1.05M1.64M1.23M1.34M1.51M2.70M5.66M5.67M6.48M5.91M5.03M
Restructuring Costs (Quarter)
Other Operating Expenses (Quarter)
-0.25M-0.00M-0.00M310.00-0.00M
Operating Expenses (Quarter)
1.96M3.80M3.21M2.72M2.86M2.92M2.55M1.54M1.24M2.12M3.34M3.91M3.67M4.62M7.29M11.34M11.79M16.81M16.45M16.57M
Operating Income (Quarter)
1.96M3.80M-62.24M2.72M2.86M2.92M2.55M-1.54M1.24M2.12M-13.13M-3.91M-3.67M-4.62M-7.29M-11.34M-11.79M-16.81M-16.45M-16.57M
EBIT (Quarter)
1.96M3.80M-62.24M2.72M2.86M2.92M2.55M-1.54M1.24M2.12M-13.13M-3.91M-3.67M-4.62M-7.29M-11.34M-11.79M-16.81M-16.45M-16.57M
Non-operating items
Non Operating Investment Income (Quarter)
-128.00-276.002.00
Interest & Investment Income (Quarter)
63.000.14M-0.15M0.85M0.12M0.10M0.67M1.03M0.93M0.95M1.02M0.92M0.86M
Other Non Operating Income (Quarter)
-0.25M0.00M0.00M310.00-0.00M-0.00M-0.01M-0.14M911.000.13M-0.12M0.00M0.00M-0.01M-0.01M-0.01M-0.00M
Net income details
EBT (Quarter)
1.84M3.45M-62.24M-2.72M2.60M2.69M2.55M-1.41M-1.11M1.95M-12.28M-3.80M-3.58M-3.96M-6.27M-10.41M-10.84M-26.79M-15.53M-85.62M
Profit After Tax (Quarter)
-1.72M3.80M-61.74M-2.72M-2.86M2.92M2.55M-1.41M-1.11M1.97M-12.19M-3.80M-3.58M-3.96M-6.26M-10.41M-10.85M-15.80M-15.50M-15.72M
Income from Continuing Operations (Quarter)
1.84M3.45M-62.24M-2.72M2.60M2.69M2.55M-1.41M-1.11M1.95M-12.28M-3.80M-3.58M-3.96M-6.27M-10.41M-10.84M-26.79M-15.53M-85.62M
Consolidated Net Income (Quarter)
1.84M3.45M-62.24M-2.72M2.60M2.69M2.55M-1.41M-1.11M1.95M-12.28M-3.80M-3.58M-3.96M-6.27M-10.41M-10.84M-26.79M-15.53M-85.62M
Income towards Parent Company (Quarter)
1.84M3.45M-62.24M-2.72M2.60M2.69M2.55M-1.41M-1.11M1.95M-12.28M-3.80M-3.58M-3.96M-6.27M-10.41M-10.84M-26.79M-15.53M-85.62M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
1.84M3.45M-62.24M-2.72M2.60M2.69M2.55M-1.41M-1.11M1.95M-12.28M-3.80M-3.58M-3.96M-6.27M-10.41M-10.84M-26.79M-15.53M-85.62M
Additional items
EPS (Basic) (Quarter)
170.79218.97-0.00M-172.75165.19163.46138.91-12.10-4.006.54-49.42-3.12-1.83-0.19-0.41-0.28-0.27-0.67-0.40-1.89
EPS (Diluted) (Quarter)
0.00M0.00M-0.07M-0.00M0.00M0.00M0.00M-0.00M-0.00M0.00M-49.42-3.12-1.83-0.19-0.41-0.28-0.27-0.67-0.40-1.89
Shares Outstanding (Quarter)
0.01M0.02M0.01M0.02M0.02M0.02M0.02M0.12M0.28M0.30M0.25M1.22M1.96M21.16M15.27M36.58M39.57M39.74M39.22M45.23M
Shares Outstanding (Diluted) (Quarter)
877.00877.00877.00877.00877.00877.00877.00877.00877.00877.000.25M1.22M1.96M21.16M15.27M36.58M39.57M39.74M39.22M45.23M
EBITDA (Quarter)
1.96M3.80M-62.24M2.72M2.86M2.92M2.55M-1.54M1.24M2.12M-13.13M-3.91M-3.67M-4.62M-7.29M-11.34M-11.79M-16.81M-16.45M-16.57M
Interest Expenses (Quarter)
0.13M0.35M0.29M0.26M0.23M0.03M0.02M0.02M0.00M0.01M0.01M0.01M-0.00M0.00M0.00M11.00M69.91M